Back to results

Evaluate the Analgesic Efficacy and Safety of VVZ-149 Injection for Postoperative Pain Following Total Hip Arthroplasty.

Primary Purpose

Post-Operative Pain

Status

Completed

Phase

Phase 2

Locations

Korea, Republic of

Study Type

Interventional

Intervention

VVZ-149 injections

Placebo

About this trial

This is an interventional treatment trial for Post-Operative Pain

Eligibility Criteria

25 Years - 65 Years (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

Patient between the ages of 25 and 65 years old
Male patient, in the case of female patient, postmenopausal women, or women physically incapable of childbearing
Subject who underwent surgery specially for the clinical study
Ability to provide written informed consent prior to any study procedures.
Ability to understand study procedures and communicate clearly with the investigator and staff.
Subjects with body weight under 100kg and body mass index (BMI) level lower than 35 kg/m2, inclusive
Single-side surgery patient

Exclusion Criteria:

< Surgical Factors >

Emergency or unplanned surgery.
Repeat operation
< Subject Characteristics >
Women with childbearing potential, Women who are pregnant or breastfeeding.
Unstable or poorly controlled psychiatric condition (e.g., untreated PTSD, anxiety, or depression). Subjects who take stable doses of antidepressants and anti-anxiety drugs may be included.
Unstable or acute medical condition (e.g., unstable angina, congestive heart failure, renal failure, hepatic failure, AIDS).
Subjects who have long QPR (>200msec) or prolonged QTc (> 450msec in male, >470msec in female) at Screening
< Drug, Alcohol, and Pharmacological Considerations >
History of alcohol, opiate or other drug abuse or dependence within 12 months prior to Screening .
Ongoing or recent (within 6 hour prior to surgery) use of steroids, opioids, or antipsychotics.
Alcohol consumption within 24 hours of surgery.
Use of nonsteroidal anti-inflammatory drugs (NSAIDs) or acetaminophen within 6 hours of surgery.
Use of herbal agents or nutraceuticals (i.e., chaparral, comfrey, germander, jin bu huan, kava, pennyroyal, skullcap, St. John's wort, or valerian) within 7 days prior to surgery.
< Anesthetic and Other Exclusion Considerations >
Use of neuraxial or regional anesthesia related to the surgery.
Use of ketamine, gabapentin, pregabalin, or lidocaine (>1 mg/kg) intra or peri-operatively, or within 24 hours of surgery.
Subject with known allergies to hydromorphone.
Subjects who received another investigational drug within 30 days of scheduled surgery

Sites / Locations

Yonsei University Health System, Severance Hospital

Arms of the Study

Arm 1

Arm 2

Arm Type

Experimental

Placebo Comparator

Arm Label

VVZ-149 injections

Placebo

Arm Description

VVZ-149 injections will be mixed with saline, then intravenous infusion for 10hr. The drug product will be administrated with a 1000mg for 10 hours.

Placebo group will receive an water for injection the same volume and period of experimental group.

Outcomes

Primary Outcome Measures

Change of Pain Intensity

Change of Pain Intensity assessed using the Numerical Rating Scale (NRS, 0-10)

Secondary Outcome Measures

Fentanyl Consumption

the amount of fentanyl consumption over 24 hours

the number of Fentanyl request

the number of PCA request over 24 hours

the amount of rescue dose

the amount of rescue dose over 24 hours

the number of requested rescue dose

the amount of requested rescue dose over 24 hours

Area under a curve (AUC) of Pain intensity and sum of AUC of pain intensity (SPI)

the calculated AUC of Pain intensity and sum of AUC of pain intensity (SPI)

Global measurement of patient satisfaction assessed on the questionnaire (0-5 points scale)

the assessment of global satisfaction of patients using 0-5 points scale

the correlation between Pharmacokinetic (PK) and Pharmacodynamic (PD)

Correlation between total opioid consumption (fentanyl dose equivalents) and plasma exposure of study drug at 0, 2, 6 hours post-PCA

Number of Vomiting

the number of vomiting after PCA

Full Information

NCT ID

NCT03347266

First Posted

November 6, 2017

Last Updated

March 11, 2019

Sponsor

Vivozon, Inc.

1. Study Identification

Unique Protocol Identification Number

NCT03347266

Brief Title

Evaluate the Analgesic Efficacy and Safety of VVZ-149 Injection for Postoperative Pain Following Total Hip Arthroplasty.

Official Title

A Randomized, Double-Blind, Parallel Group, Placebo-Controlled Study to Evaluate the Analgesic Efficacy and Safety of VVZ-149 Injection for Post-operative Pain Following Total Hip Arthroplasty

Study Type

Interventional

2. Study Status

Record Verification Date

November 2017

Overall Recruitment Status

Completed

Study Start Date

December 20, 2017 (Actual)

Primary Completion Date

July 19, 2018 (Actual)

Study Completion Date

July 19, 2018 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title

Sponsor

Name of the Sponsor

Vivozon, Inc.

4. Oversight

Studies a U.S. FDA-regulated Drug Product

Studies a U.S. FDA-regulated Device Product

Data Monitoring Committee

5. Study Description

Brief Summary

The purpose of this phase 2 study is to evaluate the efficacy and safety of an analgesic drug candidate, VVZ-149 Injections. The study is designed as randomized, double-blind, parallel, and placebo-controlled study.

Detailed Description

VVZ-149 is a dual antagonist of GlyT2 and 5HT2A. GlyT2 blockage increases inhibitory synaptic transmission by glycine in the spinal cord, resulting in a reduction of pain transmissions to the brain. 5HT2A blockage decreases descending serotonergic facilitatory modulation on pain transmission by the brain and reduces nociceptor activation in peripheral nerves, which are primary sources of pain in post-surgical pain. VVZ-149 has been shown to have comparable efficacy to morphine in well controlled (blind, complete randomization with a positive control) animal studies using rat models of post-operative pain and formalin-induced pain. The PK/PD study in animals indicates that therapeutic plasma concentration in human subjects will be 600-1,900 ng/ml. A clinical Phase 1 study performed in healthy subjects has shown no clinically significant adverse events up to a plasma concentration level of 3,261 ng/ml other than brief symptoms of mild nausea or dizziness, and mild somnolence when the plasma exposure level is more than 2,000 ng/ml.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study

Post-Operative Pain

7. Study Design

Primary Purpose

Treatment

Study Phase

Phase 2

Interventional Study Model

Parallel Assignment

Masking

ParticipantCare ProviderInvestigator

Allocation

Randomized

Enrollment

12 (Actual)

8. Arms, Groups, and Interventions

Arm Title

VVZ-149 injections

Arm Type

Experimental

Arm Description

VVZ-149 injections will be mixed with saline, then intravenous infusion for 10hr. The drug product will be administrated with a 1000mg for 10 hours.

Arm Title

Placebo

Arm Type

Placebo Comparator

Arm Description

Placebo group will receive an water for injection the same volume and period of experimental group.

Intervention Type

Drug

Intervention Name(s)

VVZ-149 injections

Other Intervention Name(s)

Colorless, transparent liquid in water for injection

Intervention Description

•VVZ-149 injection

Intervention Type

Drug

Intervention Name(s)

Placebo

Other Intervention Name(s)

water for injection

Intervention Description

water for injection

Primary Outcome Measure Information:

Title

Change of Pain Intensity

Description

Change of Pain Intensity assessed using the Numerical Rating Scale (NRS, 0-10)

Time Frame

prior to PCA, at 0,1, 2, 4, 6, 8, 10, 24 hours post-PCA

Secondary Outcome Measure Information:

Title

Fentanyl Consumption

Description

the amount of fentanyl consumption over 24 hours

Time Frame

0-2, 2-4, 4-6, 6-8, 8-10, 10-12, 12-14, 14-16, 16-18, 18-20, 20-22, 22-24 hours post-PCA

Title

the number of Fentanyl request

Description

the number of PCA request over 24 hours

Time Frame

0-2, 2-4, 4-6, 6-8, 8-10, 10-12, 12-14, 14-16, 16-18, 18-20, 20-22, 22-24 hours post-PCA

Title

the amount of rescue dose

Description

the amount of rescue dose over 24 hours

Time Frame

0-2, 2-4, 4-6, 6-8, 8-10, 10-12, 12-14, 14-16, 16-18, 18-20, 20-22, 22-24 hours post-dose

Title

the number of requested rescue dose

Description

the amount of requested rescue dose over 24 hours

Time Frame

0-2, 2-4, 4-6, 6-8, 8-10, 10-12, 12-14, 14-16, 16-18, 18-20, 20-22, 22-24 hours post-dose

Title

Area under a curve (AUC) of Pain intensity and sum of AUC of pain intensity (SPI)

Description

the calculated AUC of Pain intensity and sum of AUC of pain intensity (SPI)

Time Frame

0-1, 1-2, 2-4, 4-6, 6-8, 8-10, 10-24 hours post-PCA

Title

Global measurement of patient satisfaction assessed on the questionnaire (0-5 points scale)

Description

the assessment of global satisfaction of patients using 0-5 points scale

Time Frame

8, 24 hours post-PCA

Title

the correlation between Pharmacokinetic (PK) and Pharmacodynamic (PD)

Description

Correlation between total opioid consumption (fentanyl dose equivalents) and plasma exposure of study drug at 0, 2, 6 hours post-PCA

Time Frame

0, 2, 6 hours post-PCA

Title

Number of Vomiting

Description

the number of vomiting after PCA

Time Frame

8, 24 hours post-PCA

10. Eligibility

Sex

All

Minimum Age & Unit of Time

25 Years

Maximum Age & Unit of Time

65 Years

Accepts Healthy Volunteers

Eligibility Criteria

Inclusion Criteria: Patient between the ages of 25 and 65 years old Male patient, in the case of female patient, postmenopausal women, or women physically incapable of childbearing Subject who underwent surgery specially for the clinical study Ability to provide written informed consent prior to any study procedures. Ability to understand study procedures and communicate clearly with the investigator and staff. Subjects with body weight under 100kg and body mass index (BMI) level lower than 35 kg/m2, inclusive Single-side surgery patient Exclusion Criteria: < Surgical Factors > Emergency or unplanned surgery. Repeat operation < Subject Characteristics > Women with childbearing potential, Women who are pregnant or breastfeeding. Unstable or poorly controlled psychiatric condition (e.g., untreated PTSD, anxiety, or depression). Subjects who take stable doses of antidepressants and anti-anxiety drugs may be included. Unstable or acute medical condition (e.g., unstable angina, congestive heart failure, renal failure, hepatic failure, AIDS). Subjects who have long QPR (>200msec) or prolonged QTc (> 450msec in male, >470msec in female) at Screening < Drug, Alcohol, and Pharmacological Considerations > History of alcohol, opiate or other drug abuse or dependence within 12 months prior to Screening . Ongoing or recent (within 6 hour prior to surgery) use of steroids, opioids, or antipsychotics. Alcohol consumption within 24 hours of surgery. Use of nonsteroidal anti-inflammatory drugs (NSAIDs) or acetaminophen within 6 hours of surgery. Use of herbal agents or nutraceuticals (i.e., chaparral, comfrey, germander, jin bu huan, kava, pennyroyal, skullcap, St. John's wort, or valerian) within 7 days prior to surgery. < Anesthetic and Other Exclusion Considerations > Use of neuraxial or regional anesthesia related to the surgery. Use of ketamine, gabapentin, pregabalin, or lidocaine (>1 mg/kg) intra or peri-operatively, or within 24 hours of surgery. Subject with known allergies to hydromorphone. Subjects who received another investigational drug within 30 days of scheduled surgery

Overall Study Officials:

First Name & Middle Initial & Last Name & Degree

Seonjun Bae, MD, PhD

Organizational Affiliation

Yonsei University Health System, Severance Hospital

Official's Role

Principal Investigator

Facility Information:

Facility Name

Yonsei University Health System, Severance Hospital

City

Seoul

Country

Korea, Republic of

12. IPD Sharing Statement

Learn more about this trial

Evaluate the Analgesic Efficacy and Safety of VVZ-149 Injection for Postoperative Pain Following Total Hip Arthroplasty.

We'll reach out to this number within 24 hrs